Effective and Selective Ru(II)-Arene Complexes Containing 4,4'-Substituted 2,2' Bipyridine Ligands Targeting Human...

Area of Science:

• Organometallic Chemistry
• Medicinal Chemistry
• Cancer Research

Background:

• Cisplatin-based chemotherapy is a standard treatment for bladder cancer but causes severe side effects due to general toxicity.
• Organoruthenium complexes offer potential as anticancer agents with improved efficacy and reduced toxicity profiles.

Purpose of the Study:

• To synthesize and characterize novel water-soluble ruthenium-arene complexes with N,N'-chelating ligands.
• To evaluate the anticancer activity and selectivity of these complexes against bladder cancer cells.
• To investigate the mechanism of action and structure-activity relationships for these novel compounds.

Main Methods:

• Synthesis and characterization of seven ruthenium-arene complexes using techniques including single-crystal X-ray diffraction, UV-vis, IR, 1H NMR, and MALDI-TOF MS.
• Computational studies using DFT for structural and thermodynamic property analysis.
• Biophysical studies (DNA/protein binding) and molecular docking simulations.
• In vitro cytotoxicity assays on various human and animal cell lines, including T24 bladder cancer cells.
• Apoptosis induction studies using fluorescence imaging and flow cytometry.

Main Results:

• All synthesized complexes (1-7) showed higher cytotoxicity against T24 bladder cancer cells compared to cisplatin.
• Complexes 1 and 2 exhibited significant selectivity towards T24 cells.
• Complexes 1 and 2 were found to penetrate T24 cell membranes and induce apoptosis at their IC50 concentrations.
• Statistical analysis indicated protein binding and Log P as key factors in antiproliferation, with DNA binding being less critical.

Conclusions:

• Ruthenium-arene-2,2'-bipyridine complexes represent a novel class of potential anti-bladder cancer agents.
• Complexes 1 and 2 demonstrate promising efficacy and selectivity, warranting further investigation as chemotherapeutic drugs.
• This study provides valuable insights for the rational design of next-generation organoruthenium anticancer agents.